Vaxcyte, Inc.
PCVX
$30.65
$1.535.25%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | 75.00M | 75.00M | 75.00M | 75.00M |
| Gross Profit | -- | -75.00M | -75.00M | -75.00M | -75.00M |
| SG&A Expenses | 92.90M | 81.87M | 74.49M | 67.47M | 60.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 569.55M | 604.05M | 577.16M | 511.32M | 468.04M |
| Operating Income | -569.55M | -604.05M | -577.16M | -511.32M | -468.04M |
| Income Before Tax | -463.93M | -507.65M | -497.19M | -436.82M | -402.27M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -463.93 | -507.65 | -497.19 | -436.82 | -402.27 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -463.93M | -507.65M | -497.19M | -436.82M | -402.27M |
| EBIT | -569.55M | -604.05M | -577.16M | -511.32M | -468.04M |
| EBITDA | -562.54M | -599.03M | -573.11M | -507.88M | -464.89M |
| EPS Basic | -3.80 | -4.55 | -4.62 | -4.22 | -4.07 |
| Normalized Basic EPS | -2.37 | -2.84 | -2.89 | -2.64 | -2.55 |
| EPS Diluted | -3.80 | -4.55 | -4.62 | -4.22 | -4.07 |
| Normalized Diluted EPS | -2.37 | -2.84 | -2.89 | -2.64 | -2.55 |
| Average Basic Shares Outstanding | 487.84M | 455.17M | 433.14M | 413.95M | 388.46M |
| Average Diluted Shares Outstanding | 487.84M | 455.17M | 433.14M | 413.95M | 388.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |